CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hanx Biopharmaceuticals (Wuhan) Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hanx Biopharmaceuticals (Wuhan) Co Ltd
WUHAN, HUB  China
Business Summary
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a China-based company mainly engaged in the discovery, development and commercialization of immuno-oncology therapy. The product pipeline mainly comprises clinical stage drug candidates focused on oncology, including HX009, HX301 and HX044, as well as preclinical stage drug candidates including antibody drug conjugate, bispecific antibody and monoclonal antibody for autoimmune and oncology market. The core product HX009 is a bifunctional anti-programmed death receptor 1 (PD-1) antibody signal-regulatory protein alpha (SIRPa) fusion protein developed in-house. HX301 is a multi-targeted kinase inhibitor. HX044 is a bifunctional anti- cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (SIRPa) fusion protein. The Company is also engaged in the operation of antibody technology platform VersatiBody and autoimmune disease therapeutic platform autoRx40. The Company mainly operates its businesses in the domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024-----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman FamingZhang 60 8/22/2024 3/1/2024
Chief Executive Officer, Chief Scientific Officer, General Manager, Executive Director QixiangLi 64 8/22/2024 1/1/2022
Chief Financial Officer, Joint Company Secretary of Our Company The Secretary Of Our Board and Vice ZhangHui 56 8/1/2024 8/1/2024
9 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 136,218,830 (As of 12/31/2024)


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 19, 2025